Palmitoylethanolamide inhibits glutamate release in rat cerebrocortical nerve terminals. 2015

Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
Department of Anesthesiology, Far-Eastern Memorial Hospital, Pan-Chiao District, New Taipei City 22060, Taiwan. drlin1971@gmail.com.

The effect of palmitoylethanolamide (PEA), an endogenous fatty acid amide displaying neuroprotective actions, on glutamate release from rat cerebrocortical nerve terminals (synaptosomes) was investigated. PEA inhibited the Ca²⁺-dependent release of glutamate, which was triggered by exposing synaptosomes to the potassium channel blocker 4-aminopyridine. This release inhibition was concentration dependent, associated with a reduction in cytosolic Ca²⁺ concentration, and not due to a change in synaptosomal membrane potential. The glutamate release-inhibiting effect of PEA was prevented by the Ca(v)2.1 (P/Q-type) channel blocker ω-agatoxin IVA or the protein kinase A inhibitor H89, not affected by the intracellular Ca²⁺ release inhibitors dantrolene and CGP37157, and partially antagonized by the cannabinoid CB1 receptor antagonist AM281. Based on these results, we suggest that PEA exerts its presynaptic inhibition, likely through a reduction in the Ca²⁺ influx mediated by Ca(v)2.1 (P/Q-type) channels, thereby inhibiting the release of glutamate from rat cortical nerve terminals. This release inhibition might be linked to the activation of presynaptic cannabinoid CB1 receptors and the suppression of the protein kinase A pathway.

UI MeSH Term Description Entries
D008297 Male Males
D010169 Palmitic Acids A group of 16-carbon fatty acids that contain no double bonds. Acids, Palmitic
D011712 Pyramidal Tracts Fibers that arise from cells within the cerebral cortex, pass through the medullary pyramid, and descend in the spinal cord. Many authorities say the pyramidal tracts include both the corticospinal and corticobulbar tracts. Corticobulbar Tracts,Corticospinal Tracts,Decussation, Pyramidal,Corticobulbar Tract,Corticospinal Tract,Pyramidal Decussation,Pyramidal Tract,Tract, Corticobulbar,Tract, Corticospinal,Tract, Pyramidal,Tracts, Corticobulbar,Tracts, Corticospinal,Tracts, Pyramidal
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D004983 Ethanolamines AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives. Aminoethanols
D005089 Exocytosis Cellular release of material within membrane-limited vesicles by fusion of the vesicles with the CELL MEMBRANE.
D000577 Amides Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amide
D000700 Analgesics Compounds capable of relieving pain without the loss of CONSCIOUSNESS. Analgesic,Anodynes,Antinociceptive Agents,Analgesic Agents,Analgesic Drugs,Agents, Analgesic,Agents, Antinociceptive,Drugs, Analgesic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
August 2008, Neuroreport,
Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
March 2019, Synapse (New York, N.Y.),
Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
May 2015, Journal of medicinal food,
Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
July 2014, European journal of pharmacology,
Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
February 2009, Neurochemistry international,
Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
January 1994, The European journal of neuroscience,
Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
October 1997, The European journal of neuroscience,
Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
April 2002, Synapse (New York, N.Y.),
Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
December 2020, European journal of pharmacology,
Tzu-Yu Lin, and Cheng-Wei Lu, and Chia-Chan Wu, and Shu-Kuei Huang, and Su-Jane Wang
November 2018, Journal of biophotonics,
Copied contents to your clipboard!